Report Description of the UK Diabetes Market

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approaches for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Research Objective:

• To analyze and forecast the market size of UK Diabetes market


• To classify and forecast UK Diabetes Market based on application, drugs, project type, and application.


• To identify drivers and challenges for UK Diabetes market


• To examine competitive developments such as mergers and acquisitions, agreements, collaborations, and partnerships, etc., in UK Diabetes market


• To conduct pricing analysis for UK Diabetes market


• To identify and analyze the profile of leading players operating in UK Diabetes market

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for Renal Cell Carcinoma drug market


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Renal Cell Carcinoma market


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do deep-dive research and also provide strategy-based consulting analysis

UK Diabetes Market Executive Summary

Diabetes mellitus is a condition in which the amount of glucose in the blood is too high because the body cannot use it properly. There are two types of diabetes; Type 1 and Type 2. The most common of the two types is Type 2 diabetes and its accounts for around 90 percent of people with diabetes in the United Kingdom.

Market Size and Key Findings

The UK Diabetes market size is at around USD xx billion in 2021 and is projected to reach USD 4.33 billion by 2025, exhibiting a CAGR of xx% during the forecast period.

In the United Kingdom, there are more than a million people diagnosed with diabetes, and the number continues to grow. Diabetes is one of the biggest health challenges the United Kingdom is facing today. Growing health crisis and its complications will increase awareness of the risks, improve self-management among people with diabetes bring about wholesale changes in lifestyle and improve access to integrated diabetes care services.



Market Dynamics

Market Growth Drivers Analysis

Certain factors that are driving the growth of the market include rising diabetes mellitus in an aging population, rising prevalence of diabetes in various age groups, benefits of Insulin pump over multiple daily injections, lifestyle-compatible treatment options and technological Advancement in Insulin Pump Devices

Market Restraints

Technological advancements in insulin infusion devices, blood glucose meter accuracy problem, low compliance of glucose monitoring & inadequate reimbursement for SMBG supplies, safety Issues in insulin pump devices, and difficulties associated with the pump

Competitive Landscape

Key Players

The key companies operating in the market include Company profiles, Abbott, Roche, Johnson & Johnson, Dexcom, Medtronic, ARKRAY, Inc., Ascensia Diabetes Care, AgaMatrix, Bionime Corporation Novo Nordisk, Eli Lilly, Sanofi, Rossmax International Ltd and Others

Products in Pipeline

Despite the type 1 diabetes (T1D) pipeline promising to deliver innovative therapies over the next decade to improve disease management, there will still be high levels of unmet need relating to the lack of a disease-modifying therapeutic that combats the autoimmune-mediated attack of beta cells in T1D patients.

Notable Recent Deals

Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with insulin dosing information for future smart pens, insulin titration apps and cloud software.

Healthcare Policies and Regulatory Landscape

Pricing and Reimbursement scenario of UK Diabetes Market

England implemented the National Service Framework for Diabetes (NSF-D), with seven main objectives including prevention and early diagnosis, decision-making via patient empowerment, quality of care during adulthood and childhood, treating diabetic emergencies and inpatient care, pregnancy care, and complications management. The NSF-D is supported by QOF, encouraging, among other things, diabetes data collection, alongside the annual National Diabetes Audit, which reports key indicators.